Statistics on veterinary medicines

27.03.2019

Overview of Estonian Veterinary Medicinal Products Market

Veterinary drug statistics is based on wholesaler’s reports. The statistics of veterinary medicinal products includes sales to general and veterinary pharmacies, veterinarians and to other institutions.

WHOLESALERS

In 2018 10 wholesalers sold veterinary medicines to general and veterinary pharmacies, veterinarians and to other institutions. As shown below two largest wholesalers covered over 83% and four largest wholesalers covered approximately 98% of the total veterinary medicinal products market and the share of the rest of wholesalers was modest.

Wholesaler	2014	2015	2016	2017	2018
Zoovetvaru OÜ	46.2%	40.7%	46.0%	49.6%	50.7%
Magnum Veterinaaria AS	26.2%	29.0%	29.4%	29.8%	32.2%
Dimedium AS		9.6%	17.7%	15.5%	12.6%
Optimer AS	2.5%	3.3%	3.6%	3.6%	2.9%

VETERINARY MEDICINAL PRODUCTS MARKET

The veterinary medicinal products market is expressed in wholesale prices which includes the price of the manufacturer and wholesaler’s mark-up without the VAT.

The veterinary medicinal products market increased 6-9% in years 2012-2014. In 2015 the total sales decreased 5%. Since 2016 the sales increased again compared to previous year respectively 7.8%, 8.0% and 13.3%, reaching in 2018 to 14.13 million euros.

Figure 1. Estonian veterinary products market in 2014–2018

VETERINARY MEDICINAL PRODUCTS MARKET SHARE

Sales to the veterinary doctors or to the agricultural companies represented by veterinary doctor covered 87% (12.25 million euros) of the total veterinary medicinal products market in 2018. Almost 7% (0.97 million euros) of veterinary medicines were sold to the veterinary pharmacies and 5% (0.71 million euros) to the general pharmacies. Sales to the other institutions were 1% (0.20 million euros).

Figure 2. Sales of veterinary medicinal products in 2014–2018

VETERINARY MEDICINAL PRODUCTS MARKET SHARE BETWEEN ATCvet GROUPS

Based on ATCvet classification three largest ATCvet groups covered 68% of total veterinary medicinal products market: antiinfectives 26.8% (3.79 million euros), antiparasitic products 20.6% (2.91 million euros) and immunologicals 20.4% (2.88 million euros), followed by musculo-sceletal system (1.18 million euros), alimentary tract and metabolism (1.17 million euros) and genito urinary system and sex hormones (0.58 million euros). The rest of the ATCvet groups covered 11% of the total veterinary medicines market.

Figure 3. Estonian veterinary medicinal products market share between ATCvet groups in 2016–2018

ANTIINFECTIVES FOR SYSTEMIC USE

Turnover of antiinfectives

The turnover of antiinfectives increased until 2014, decreased considerable in 2015: compared to the previous year -19%, and stayed the same level in 2016–2017. In 2018 the turnover increased 16% compared to the previous year.

The most sold antibacterials for systemic use by turnover were third-generation cephalosporins (QJ01DD), fluoroquinolones (QJ01MA) and penicillins with extended spectrum (QJ01CA). The turnover of pleuromutilins (QJ01XQ) had considerable increase in 2014 and 2018.

Figure 4. Turnover of most sold antibacterials in 2014–2018

The amount of sold antiinfectives by active ingredient

The turnover of antibacterials increased 16% compared to the previous year, but the amount of sold active ingredients remained the same level compared to the year 2017 (6.5 tons in 2017 and 2018).

Figure 5. The total amount of sold antibiotics in 2009–2018

The most sold groups of antibiotics are penicillins, tetracyclines, pleuromutilins and aminoglucosides: in 2018 the share was respectively 33%, 21%, 16% and 7% of total antibacterials sold for veterinary use.

Figure 6. Antibiotics for veterinary use in 2009–2018

The most sold active ingredients in 2018 were Amoxicillin, Tiamulin, Doxycycline and Benzylpenicillin.

Table 1. The most sold active ingredients (antibiotics) in 2009–2018 (sold in kilograms)

	Active ingredient	2012	2013	2014	2015	2016	2017	2018
1	Amoxicillin	1923	2676	2215	2803	2969	1701	1321
2	Tiamulin	561	512	1827	931	728	692	1047
3	Doxycycline	1474	1460	1875	1577	1526	1380	1042
4	Benzylpenicillin	667	737	786	679	612	683	742
5	Dihydrostreptomycin	534	448	392	373	343	353	339
6	Tylvalosin	66	61	298	161	169	180	304
7	Oxytetracycline	276	239	282	386	204	178	242
8	Sulfamethoxazole	0	150	0	0	0	205	218
9	Sulfadiazine	46	49	72	64	91	90	121
10	Spectinomycin	180	313	466	143	42	67	114
11	Chlortetracycline	57	66	66	69	103	117	111
12	Marbofloxacin	26	37	46	50	75	84	93
13	Ceftiofur	56	66	68	63	68	76	89
14	Paromomycin	0	0	0	12	30	43	87
15	Colistin	540	697	397	137	83	109	83

ANTIPARASITIC PRODUCTS

In the last ten years the turnover of antiparasitic products has been constantly increasing – more than twice in ten years, reaching 2.9 million euros in 2018.

Figure 7. Turnover of antiparasitic products in 2014–2018

IMMUNOLOGICALS

In 2014–2018 the turnover of immunologicals remained between 2.5–2.9 million euros. 52% of immunologicals sold in 2018 were immunologicals for suidae.

Figure 8. Turnover of immunologicals in 2014–2018

HUMAN MEDICINES FOR VETERINARY USE

In the absence of authorised veterinary medicine, veterinarian can use authorised human medicine if necessary. The most sold human medicines for veterinary use were drugs for sensory organs and nervous system, followed by drugs for blood and blood forming organs and antiinfectives for systemic use.

Figure 9. Human medicines sales for veterinary use in 2018